Cancer-Associated Stroke: Combinatorial Approach to Dysfunctional multi-target signalling modulEs

Cancer-Associated Stroke: Combinatorial Approach to Dysfunctional multi-target signalling modulEs - CASCADE

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00035828

Enrollment

Registered

2025-01-21

Start date

2025-01-06

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

I63 I64 C34

Interventions

Group 1: Group1 Transcriptome analysis of PBMCs isolated from blood of lung cancer patients. Analysis of blood plasma. No interventional analysis. Group 2: Group2 Transcriptome analysis of PBMCs isola

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Stroke event must occur within first year after tumor diagnosis

Exclusion criteria

Exclusion criteria: autoimmune disorders, immunosuppressant intake

Design outcomes

Primary

Measure	Time frame
Development of a transcriptomics-based strategy to identify altered gene regulatory mechanisms involved in the pathomechanism of lung cancer-associated stroke.	—

Secondary

Measure	Time frame
Development and validation of novel therapeutic strategies based on molecular mechanisms using an in silico-based network-pharmacology approach.	—

Countries

Germany

Contacts

Public ContactAna Isabel Casas Guijarro

Klinik für Neurologie

anaisabel.casasguijarro@uk-essen.de+49 201 723 7124

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 7, 2026